<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have shown the possibility to modulate various anemic syndromes during acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> differed in pathogenesis and induced by graft versus host reaction (GVHR) </plain></SENT>
<SENT sid="1" pm="."><plain>There are different variants of combined erythro- and immunopoiesis disorders in the semiallogeneic system <z:chebi fb="28" ids="35299">DBA</z:chebi>/2 --&gt; B6D2F1: <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> plus <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> and <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> plus <z:hpo ids='HP_0001878'>hemolytic anemia</z:hpo> plus immunocomplex <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In the allogeneic system C57BL/6 --&gt; BALB/c there is <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> plus <z:hpo ids='HP_0001908'>hypoplastic anemia</z:hpo> with reduced bone marrow erythropoiesis </plain></SENT>
<SENT sid="3" pm="."><plain>Differences in pathogenesis of anemic syndrome are connected with the functional properties of macrophages and cytokine production by macrophages </plain></SENT>
<SENT sid="4" pm="."><plain>There is some positive effect of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0005039'>hypoxia</z:mp> on GVHR-induced <z:mpath ids='MPATH_188'>immunopathology</z:mpath> in B6D2F1 mice: it increases humoral immune response, has favorable effect on <z:hpo ids='HP_0001903'>anemia</z:hpo> and corrects early and late committed precursor number </plain></SENT>
<SENT sid="5" pm="."><plain>The absence of any influence of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0005039'>hypoxia</z:mp> on the secreted activity of macrophages gives an evidence to the direct influence of erythron on the humoral immune response </plain></SENT>
<SENT sid="6" pm="."><plain>VM-2-84 has favorable effect on <z:hpo ids='HP_0001903'>anemia</z:hpo> (suppresses IL-1 production, reduces the number of early erythroid precursors and stimulates the amount of the granulocyte and macrophage precursors) in B6D2F1 mice with <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The compound from alkancarboxylic acids - VM-2-84, up to two months decreases <z:hpo ids='HP_0000093'>proteinuria</z:hpo> and reduces proliferation of mezangiocytes and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> with the restoration of immune system </plain></SENT>
<SENT sid="8" pm="."><plain>Trecrezan, while having beneficial effect on <z:hpo ids='HP_0001903'>anemia</z:hpo>, reduces a <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> of erythron in mice with <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>; it influences the production of monokines </plain></SENT>
<SENT sid="9" pm="."><plain>The obtained facts about effectiveness of preparation possessing combined erythro- and immunopoiesis-modulating properties, open new ways of a target regulation of disorders of immunity </plain></SENT>
</text></document>